TriangleAnti-VEGF Monoclonal Antibody (NCT07504588)
Anti-VEGF Monoclonal Antibody trial for Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma (NCT07504588). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for women aged 18 or older with platinum-sensitive, high-grade serous or endometrioid ovarian, fallopian-tube or primary peritoneal cancer. Tumors must be BRCA1/2-mutant or homologous-recombination deficient, progressing during first-line PARP-inhibitor maintenance without intervening treatment. Prior topoisomerase-I inhibitors are excluded.
The idea: compare sacituzumab govitecan plus bevacizumab against carboplatin plus either pegylated liposomal doxorubicin or gemcitabine, alongside bevacizumab. Sacituzumab govitecan delivers DNA-damaging chemotherapy to TROP2-bearing cells; bevacizumab blocks blood-vessel growth.
This phase 2 study plans 87 patients. Rebecca Porter leads; 19 recruiting US locations are listed.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.